US20170015719A1 - Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest - Google Patents
Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest Download PDFInfo
- Publication number
- US20170015719A1 US20170015719A1 US13/952,068 US201313952068A US2017015719A1 US 20170015719 A1 US20170015719 A1 US 20170015719A1 US 201313952068 A US201313952068 A US 201313952068A US 2017015719 A1 US2017015719 A1 US 2017015719A1
- Authority
- US
- United States
- Prior art keywords
- protein
- fragment
- cells
- polynucleotide according
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 78
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 78
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 66
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 53
- 108010079723 Shiga Toxin Proteins 0.000 title claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 84
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 34
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 230000010189 intracellular transport Effects 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 13
- 230000003993 interaction Effects 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 9
- 102000034342 Calnexin Human genes 0.000 claims description 8
- 108010056891 Calnexin Proteins 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 8
- 108700012359 toxins Proteins 0.000 claims description 8
- 230000032258 transport Effects 0.000 claims description 8
- 230000007441 retrograde transport Effects 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 108700020796 Oncogene Proteins 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 108010067390 Viral Proteins Proteins 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 206010044696 Tropical spastic paresis Diseases 0.000 claims 2
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 230000007124 immune defense Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 210000004443 dendritic cell Anatomy 0.000 description 18
- 239000012528 membrane Substances 0.000 description 17
- 210000002288 golgi apparatus Anatomy 0.000 description 14
- 238000010276 construction Methods 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 10
- 230000035800 maturation Effects 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 230000004988 N-glycosylation Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 5
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010006519 Molecular Chaperones Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010017898 Shiga Toxins Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 2
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 101710091881 GTPase HRas Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101710136524 X polypeptide Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000047279 human B2M Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Definitions
- the invention relates to means and to their use for intracellular transport of proteins or polypeptides, also to the membrane presentation of certain epitopes.
- Retrograde transport can be defined as the movement of molecules from the cell membrane to the endoplasmic reticulum (ER), passing if necessary via the Golgi apparatus. This mechanism has been demonstrated for certain classes of proteins of the endoplasmic reticulum carrying the tetrapeptide KDEL at the carboxy terminal (or HDEL in starch). A great deal of biochemical and morphological evidence indicates that those proteins leave the endoplasmic reticulum, reach the Golgi apparatus in which modifications are made to their carbohydrate chain and are then redirected to the endoplasmic reticulum.
- the tetrapeptide KDEL is a retention signal which traps the peptide or protein to which it is attached in the endoplasmic reticulum, such trapping taking place by interaction at a receptor protein for the KDEL motif described by Lewis M. J. et al in Nature, 348 (6297): 162: 3, 1990, 8 th November.
- Such toxins are composed of two polypeptide chains; one (the A fragment) is the toxic fragment and carries a deadenylase activity which inhibits protein synthesis by acting on the 28S ribosomal RNA, while the other sub-unit (the B fragment) enables the toxin to bind to the target (O'Brien et al (1992), Curr. Top. Microbiol. Immunol. 180: 65-94). Electron microscope studies have shown that Shiga toxin can be detected in the ER of A431, Vero, and Daudi cells in particular (Sandvig et al 1992 and 1994; KHINE, 1994).
- Intracellular transport is defined as the ensemble of exchanges between the different cellular compartments.
- the authors of the present application have observed that the B fragment is not only moved towards the ER, but also to the nucleus of hematopoietic lines, in particular dendritic cells and macrophages.
- the present invention results from observations on intracellular transport of the B fragment of Shiga toxin (B fragment) and uses its routing properties to construct a chimeric polypeptide sequence containing:
- coupling can be via a strong non covalent interaction.
- the cDNA of the B fragment is fused with that of streptavidin or with any other avidin derivative using known methods (Johannes et al (1987), J. Biol. Chem., 272: 19554-19561).
- the protein resulting from fusion can react with biotinylated DNA obtained by PCR using biotinylated primers, or with any other biotinylated substance.
- the resulting complex is bound to target cells and should be transported like the intracellular B fragment.
- a further coupling method employs site-specific biotinylation of the B fragment.
- the cDNA of the B fragment is fused with cDNA coding for the BirA enzyme recognition site Boer et al (1995), J. Bacterial, 177: 2572-2575; Saou et al (1996) Gene, 169: 59-64).
- the B fragment is bound to other biotinylated molecules (such as cDNA, see above) via streptavidin or any other tetravalent avidine derivative.
- the term “functional equivalent” means any sequence derived from the B fragment by mutation, deletion or addition, and with the same routing properties as the B fragment.
- a functional equivalent can be constituted by any fragment with the same retrograde transport properties and even intracellular transport to the nucleus as those described for the B fragment.
- Examples which can be cited are the B fragment of verotoxin described in the Proceedings of the National Academy of Sciences of the United States of America, 84 (13): 4364-8 1987, July, or the B fragment from ricin described by Lamb F. I. Et al in the European Journal of Biochemistry, 148(2): 265-70 (1995).
- the skilled person will be able to select the fragment which would be the best candidate as a vector for routing any sequence in any cellular compartment.
- the present invention encompasses the use of the B fragment of Shiga toxin or any other sub unit of bacterial toxins which would have comparable activities, in particular routing properties analogous to those of fragment B, including polypeptides miming the Shiga toxin B fragment.
- These polypeptides, and in general these functional equivalents can be identified by screening methods which have in common the principle of detecting the interaction between random peptide sequences and the Gb 3 receptor or soluble analogues of the receptor.
- phage libraries expressing random peptide sequences for selection on affinity columns comprising Gb 3 or after hybridisation with soluble radioactive Gb 3 analogues can be used.
- the glycolopid Gb 3 has been identified as being the cellular receptor of the Shiga toxin (Lingwood (1993), Adv. Lipid Res., 25: 189-211). Gb 3 is expressed by cells which are sensitive to the toxin and internalisation of the toxin would be permitted by an interaction with Gb 3 .
- the present inventors have demonstrated that in HeLa cells in which expression of the Gb 3 receptor has been inhibited ( FIG. 1A ), the internalised B fragment is not transported into the Golgi apparatus but is accumulated in vesicular structures in the cytoplasm, principally represented by lysosomes. In the control cells, the B fragment is transported to the Golgi apparatus ( FIG. 1B ).
- the inventors have demonstrated that in the presence of an inhibitor of Gb 3 receptor synthesis, PPNP (+PPNP), up to 50% of the internalised B fragment is degraded in the form of TCA-soluble material, which conforms to a transport activity towards a subsequent degradation compartment such as an endosomal or lysosomal compartment.
- PPNP an inhibitor of Gb 3 receptor synthesis
- ⁇ PPNP Gb 3 receptor synthesis
- a much smaller proportion of internalised B fragment becomes TCA soluble. It can thus be concluded that the presence of the Gb 3 receptor is necessary for addressing the B fragment to specific compartments, which tends to favour the fact the main factor in the activity of the B fragment is its binding to the Gb 3 receptor.
- the present invention provides chimeric polypeptide sequences, said sequences comprising at least: the Shiga toxin B fragment or a functional equivalent thereof the carboxy-terminal end of which has bound to it one or more X polypeptides with the following formula:
- the present invention also provides chimeric molecules with the following structure:
- X′ represents a nucleotide sequence coding for a peptide sequence X the expression of which is desired, in particular an antigen epitope.
- the chimeric molecules of the invention can also comprise:
- chimeric polypeptide sequences can comprise:
- the chimeric molecules of the invention enable X sequences or the expression product of X′ to be routed in the ER.
- retrograde transport also occurs via the Golgi apparatus and probably via the endosomes.
- the molecules of the invention can undergo maturation leading to a membrane presentation of certain epitopes contained in the chimeric polypeptide sequence.
- Maturation means any process which, from a given polypeptide, leads to the emergence of peptides which themselves can be presented in a cellular compartment including the cytoplasm. Maturation can occur either by enzymatic clipping in the endoplasmic reticulum, or by transport into the cytoplasm in which the polypeptide is cleaved then the peptides obtained are again transported in the endoplasmic reticulum.
- Molecules of the class I major histocompatibiliry complex can become charged with polypeptide molecules of interest X or X′ after such cleavage and be presented on the cellular membranes.
- the chimeric molecule of the invention consists of coupling a B fragment or its equivalent with a polynucleotide molecule or an expression vector comprising a sequence the expression of which is desired, after transcription in the nucleus then translation in the cytoplasm, the polypeptide which is synthesised can undergo the same steps of cleavage, maturation and intracellular transport as that described above for a polypeptide chimeric sequence.
- Chimeric polypeptide molecules in accordance with the invention can constitute an active principle in a therapeutic composition for immunotherapy by a mechanism which is close to biological processes regarding antigen presentation suitable for development of the immune reaction.
- the X fragment thus represents one or more epitopes for which membrane presentation is desired at the cell surface.
- the size of the X fragment is limited only by the intracellular transit capacity of the chimeric molecules under consideration.
- This approach can be envisaged both for an anti-infectious or an anti-cancer immunotherapy and for constituting an antigenic bait in certain autoimmune diseases.
- Any type of antigen presented by cl I MHC is a good candidate for selecting simple or chimeric epitopes which form part of the constructions of the invention. Examples which can be cited are:
- epitopes can be selected from those described by Chiez, R. M. et al (1994) in Immunol. Today 15, 155-60.
- X or the expression product of X′ can also represent a polypeptide sequence which can restore an intracellular transport function which has been perturbed by whatever cause.
- a biological molecule can be trapped in the ER due to a modification by mutation, deletion or addition of a sequence, having the effect of blocking maturation or transit of that molecule. This is the case, for example, with mutated CFTR ( ⁇ F508) 15 where binding to a chaperone molecule such as calnexin is modified such that its release is prevented or retarded, thus preventing intracellular transit.
- This mutation is the cause of cystic fibrosis.
- the invention also provides nucleic acid constructions, in particular DNA or cDNA comprising a sequence of nucleotides coding for the chimeric protein the structure and variations of which have been defined above. More particularly, the invention provides expression vectors or plasmids carrying the above constructions and capable of being expressed in bacterial cultures.
- the expression vector can be the pSU108 plasmid described by G. F. Su et al (1992), Infect. Immun. 60: 3345-59.
- constructions comprising:
- the construction can also comprise any nucleic acid sequence coding for a polypeptide the presence of which enables proper intracellular transport in cells intended to be treated by the molecules of the invention.
- it may be:
- the polynucleotide construction of the invention is under the control of a promoter, preferably a strong promoter which can produce the correct degree of expression in bacteria into which it has been transfected.
- the invention also provides transfected bacteria comprising these constructions, and capable of producing the chimeric polypeptides or proteins of the invention.
- the host cells treated by the molecules of the invention also form part of the invention; they may be any type of cell, in particular:
- the chimeric molecules of the invention allow a novel therapeutic method to be postulated which can overcome the problems linked to viral vectors or retroviral vectors which are normally used to integrate and express exogenous molecules in animal cells.
- the therapeutic method which derives from the molecules of the invention consists of directly treating the cells of a patient, either ex vivo or by direct stereotaxic application with the chimeric polypeptide sequences, or by conventional mucosal treatment methods such as aerosols.
- the invention concerns the use of chimeric polypeptide or polynucleotide sequences coding for the polypeptides of the invention in the production of therapeutic compositions in which particular polypeptides are expressed in the membranes of target cells.
- These polypeptides are advantageously epitopes against which the development of an immunological reaction is desired which are then presented on the surface of the immune system cells, in particular dendritic cells, macrophages or B lymphocytes.
- the B fragment of the Shiga toxin acts as an epitope vector enabling cells presenting antigens to be programmed.
- the present invention concerns an immunotherapeutic method consisting of increasing cellular immunity as the result of the presence of an undesirable antigen in an organism, said method consisting of causing key cells of the immune system, such as dendritic cells and macrophages, to express particular epitopes.
- the treatment method of the invention is aimed at triggering immunity to cellular and humoral mediation by charging the cl I or cl II MHC molecules with the epitopes of interest, after restriction in the target cells. This leads to activation of cytotoxic T cells against the antigen which it is desired to eliminate.
- the epitopes presented through the constructions of the invention originate from viral, parasitic or bacterial antigens or from any cell, organite, or micro-organism the elimination of which is desired, such as cancer cells or infected cells.
- the epitopes can also act as bait enabling “self” molecules recognised as foreign. antigens in autoimmune diseases to be replaced by the epitopes of the invention, thus slowing down or reducing the immune reaction.
- the invention also concerns the use of the chimeric molecules of the invention in the manufacture of therapeutic compositions in which the particular polypeptides which it is desired to express can restore intracellular transit of a protein the altered structure of which leads to it being trapped in the ER and to an expression deficit. This is the case for membrane expression proteins which undergo intracellular maturation, including glycosylations, sulphatations, folding etc.
- a particular example is that of mutated CFTR (A F508) wherein the attachment of a chaperone molecule such as calnexin is modified following modification of the protein; this leads to the molecule being trapped, causing cystic fibrosis, leading to a general insufficiency of exocrin secretions, in particular in the pancreas and lungs.
- a chaperone molecule such as calnexin
- the present invention concerns a therapeutic treatment method for diseases having an origin in a fault in protein secretion; the method consists of directly administering the chimeric polypeptides or administering the genetic information to the cells of patients in the form of plasmids carrying exogenic sequences coding for a peptide or polypeptide which can restore the deficient cellular function.
- This restoration can result either in supplementation of the deficient function by the polypeptide X or competition between the mutated protein and the polypeptide synthesised from the exogenic sequence for binding with a specific molecule or receptor of the cellular machinery.
- a particular example is the treatment of the mutant cited above, causing cystic fibrosis, by administering a vector carrying a sequence coding for the attachment site for the CFTR protein with its chaperone molecule or by direct administration of the chimeric polypeptide.
- the constructions of the invention endow the human or animal health world with a novel therapeutic means for treating diseases caused by a deficit in intracellular transit or for increasing or inducing a membrane presentation of a molecule, a polypeptide or an epitope of interest.
- FIG. 1A HeLa cells in which expression of the Gb 3 receptor has been inhibited.
- the internalised B fragment is not transported to the Golgi apparatus but is accumulated in the vesicular structures.
- FIG. 1B Control HeLa cells in which the B fragment is transported to the Golgi apparatus.
- FIG. 2 Biochemical test showing the defect in B fragment transport.
- FIG. 3 MHC class I restricted presentation of Shiga B-Mage 1 fusion proteins at peripheral blood monocytic cells (PBMC): role of the KDEL sequence.
- the PBMC (5 ⁇ 10 4 ) were primed overnight with either Mage 1 peptide (1 ⁇ M) or Mart 1 peptide (1 ⁇ M) or Shiga B-Mage 1 fusion proteins (1 ⁇ M) with a sequence which is active (B-Mage 1-Glyc-KDEL) or inactive (B-Mage 1-Glyc-KDELGL) for recycling to the endoplasmic reticulum.
- cytotoxic T cells specific for the Mage 1 epitope (clone 82/30) were incubated with PBMC cells primed for 24 hours. The supernatants were then collected and tested for the production of ⁇ interferon.
- FIG. 4 MHC class I restricted presentation of the Shiga B-Mage 1 fusion protein by different types of cells presenting antigens.
- B lymphoblastoid cells ( ), dendritic cells (+) or clonal T cells ( ) were primed with the soluble Shiga B-Mage 1 fusion protein, as for FIG. 3 .
- Presentation of Mage 1 peptides was tested using the 82/30 CTL line.
- FIG. 5 Analysis of the specificity of the MHC class I restricted presentation of the Shiga B-Mage 1 fusion protein by lines of B lymphoblastoid cells.
- Cells from the BM21 (HLA-A1) or BV1 (HLA-A2) B lymphoblastoid line were primed overnight either with medium alone or with Mage 1 or Mart 1 synthetic peptides (1 ⁇ M, or with ShigaB-Mage 1 fusion protein (1 ⁇ M), or with Antp-Mage 1 fusion protein or with the B fragment of wild-type Shiga toxin.
- specific cells of Mage 1 TCL 82/30 (A) or Mart 1 CTL LB373 (B) were incubated for 24 hours with primed B-EBV cells. The supernatants were then collected and tested for the production of ⁇ interferon.
- the X epitope selected was the MAGE epitope, present in cancer cells of patients with melanoma.
- the plasmid used was the pSU1O8 plasmid described by Su et al, 1992, Infect. Immun. 60: 33-45, 3359.
- PCR primers used were as follows:
- SEQ ID No. 1 5′-ACTAGCTCTGAAAAGGATGAACTTTGAGAATTCTGACTCAGAATAG CTC-3′
- SEQ ID No. 2 5′-CTTTTCAGAGCTAGTAGAATTAGGATGATAGCGGCCGCTACGAAAA ATAACTTCGC-3′
- the primers were used with specific primers from the ShigaAtpE (5′) vector
- SEQ ID No. 3 5′-CACTACTACGTTTTAAC-3′
- SEQ ID No. 4 5′-CGGCGCAACTATCGG-3′ to produce fragments which were cloned at the restriction sites SphI and SaII of the SU108 plasmid.
- the resulting fragments were cloned at the NotI and EcoRI restriction sites of pSU108 and containing the cDNA coding for B-Glyc-KDEL.
- E. coli cells containing recombinant expression plasmids obtained from pSU108 were cultured overnight at 30° C. The culture was then diluted 5 times in LB supplemented with 50 mg/ml of ampicillin, at 50° C.
- the cells were thoroughly washed with 10 mM Tris/HCL, pH 8, incubated for 10 minutes in 10 mM Tris/Hcl, pH 8; 25% sucrose, 1 mM EDTA, and finally rapidly re-suspended in a water-ice mixture containing 1 mM of PMSF and a protease inhibitor mixture (leupeptin, chymostatin, pepstatin, antipain and aprotinin). The final step led to rupture of the periplasm. After clarification, the supernatant was charged onto a QFF column (Pharmacia) and eluted with a linear gradient of NaCl in 20 mM Tris/HCl, pH 7.5.
- a protease inhibitor mixture leupeptin, chymostatin, pepstatin, antipain and aprotinin
- the B fragment was eluted between 120 mM and 400 mM.
- the fractions containing the B fragment were then dialysed against 20 mM of Tris/HCl, pH 7.5, and re-charged onto a monoQ column (Pharmacia) and eluted in the same manner as before.
- the resulting proteins estimated to have a degree of purity of 95% using polyacrylamide-SDS gel 15 electrophoresis, were then stored at ⁇ 80° C. until use.
- Dendritic cells were cultured using previously established protocols (Romani et al, 1994). Briefly, PBMC were taken up into suspension in Iscove medium and incubated for 2 h at 37° C. in 6-well trays. Cells which had not adhered were removed and the remaining cells were incubated at 37° C. in the presence of GM-CSF (800 U/ml) and IL-4 (500 U/ml). After 5 days culture, the IL-1 ⁇ and IFN- ⁇ in respective concentrations of 50 U/ml and 150 U/ml were added and incubation was continued at 30° C. for 24 h.
- GM-CSF 800 U/ml
- IL-4 500 U/ml
- the dendritic cells were then taken up into suspension in Iscove medium in the presence of increasing concentrations of B fragment coupled with the MAGE epitope and in the presence of 3 ⁇ g/ml of human ⁇ 2-microglobulin to improve the capacity of the cells to presentation of membrane epitopes.
- This mixture was incubated at 30° C. for 4 hrs.
- DCs which had internalised the B fragment coupled to this epitope were irradiated at 5000 rad, assembled by centrifuging, taken up into suspension, and mixed with CD8 + lymphocytes (prepared from PBMC). These DC, pulsed with an antigen, and the CD8 + were then kept in co-culture in the presence of 5 ng/ml of IL-7.
- responsive CD8 + lymphocytes were re-stimulated by freshly prepared irradiated DCs which were then also incubated in the presence of increasing concentrations of fragment B coupled to the same epitope.
- the co-culture of DC and responsive CD8 + lymphocytes was continued in the presence of IL-2 and IL-7 in concentrations of 10 U/ml and 5 ng/ml respectively. This re-stimulation protocol was repeated 3 times.
- responsive CD8 + lymphocytes pre-stimulated as described above were incubated in the presence of cancer cells or cells infected with a virus. These cells, which expressed the selected epitope, were labelled with Na 2 51 CrO 4 then brought into contact with responsive CD8 + for 5 hours (Bakker et al, 1994). The radioactivity released in the medium was then determined, enabling the cytotoxic activity of the pre-stimulated responsive CD8 + lymphocytes to be quantified.
- B-MAGE-Glyc-KDEL The novel protein was designated B-MAGE-Glyc-KDEL.
- the B-MAGE-Glyc-KDEL protein was coupled with the fluorophore DTAF in order to follow its intracellular transport by confocal microscopy. After internalistion, this protein was detectable in the Golgi apparatus and in the ER of HeLa cells and Pena-EBV cells (a B lymphocyte line immortalised using the Epstein-Barr virus).
- N-glycosylation is a modification which is carried out specifically in the ER, and we have demonstrated above that a B fragment carrying a recognition site for N-glycosylation is in fact glycosylated if it is transported to the ER.
- cytotoxic T lymphocyte clone specifically recognising the MAGE-1 epitope associated with MHC class I of cells presenting the HLA-A1 haplotype.
- CTL cytotoxic T lymphocyte clone
- the quantity of IFN ⁇ secreted is proportional to the amplitude of the stimulation of the CTLs by the presenting cells.
- Presenting cells (Pena-EBV and dendritic, 20000 cells per round bottom microwell) were either fixed for 1 h with 4% PBS-paraformaldehyde, or were not fixed. They were than washed twice with OptiMEM before being incubated for 15 h with dilutions of the B-MAGE-Glyc-KDEL protein. The protein was tested at 4 dilutions, starting with a concentration of 10 ⁇ mM final, and diluting 5 in 5 in the OptiMEM medium (medium without serum). After 15 h, the plates were washed twice by low speed centrifuging.
- the CTL (CTL 82/30) were added in an amount of 5000 CTL per well in 100 ⁇ l of culture medium (ID-HS-AAG+25 U/ml of IL2). As a positive control, some CTL 82/30 were kept in the presence of line G43 (a B lymphocyte line transfected with an expression plasmid of MAGE-1). After 24 h of incubation, the supernatants were harvested to determine the quantity of IFN ⁇ produced.
- line G43 a B lymphocyte line transfected with an expression plasmid of MAGE-1
- Mouse dendritic cells were prepared and marked with an antigen derived from P21RAS, P53 or EP2/NER proteins to test the anti-tumoral activity, or HBV, EBV or HPV to test antiviral activity. This preparation of dendritic cells was carried out using the protocol described in 1-4) above.
- the antiviral or anti-tumoral effect was observed by subsequent treatment of these mice grafted with tumoral cells or virus expressing this antigen.
- polypeptide sequences or polynucleotide sequences of the invention can thus advantageously constitute an active principle in a pharmaceutical composition intended for the treatment of certain cancers or certain viral or bacterial infections, from the moment when a particular epitope of said virus or said cancer cell will have been integrated into the recombinant nucleotide sequence, leading to synthesis of a chimeric polypeptide which can be restricted by the MHC class I and can be expressed on the membrane surface of immune system cells.
- the CFTR (cystic fibrosis transmembrane regulator) protein is a chlorine channel of the plasmic membrane.
- the CFTR gene carries mutations.
- the mutation ( ⁇ F508) which is the most frequently observed affects intracellular routing of the CFTR protein.
- the mutated protein CFTR( ⁇ F508) which is functional as regards its ionic channel activity, remains blocked at the endoplasmic reticulum, instead of being transported to the plasmic membrane.
- a chimeric protein composed of a B fragment and the interaction domain derived from the CFTR protein.
- a recycle signal (the KDEL peptide) was added to the carboxy-terminal end of this protein to increase its retention in the endoplasmic reticulum. It was first verified that the novel protein was also transported in the endoplasmic reticulum of target cells. Mobilisation of CFTR( ⁇ F508) was studied in cells of a stable cell line, LLCPKI, transfected with the cDNA of CFTR( ⁇ F508). This line was established by Mlle. M. A. Costa de Beauregard and M. D. Louvard (Institut Curie, Paris, CNRS UMR 144).
- the CFTR ( ⁇ F508) protein which was expressed in these cells was also endowed with an epitope tag. It was thus possible to detect the arrival of the CFTR ( ⁇ F508) protein in the plasmic membrane by immunofluorescence. In the absence of treatment, the plasmic membrane of LLCPKI cells of the line was depleted with specific CFTR ( ⁇ F508) tags in the plasmic membrane. While the results of these pilot experiments are promising, we are obliged to develop this approach within the context of cystic fibrosis therapy.
- the synthetic polypeptide in which X is constituted by an interaction domain between the CFTR protein and calnexin can advantageously constitute the active principle of a therapeutic composition intended to treat cystic fibrosis.
- competition between the mutated interaction domain in the mutant and the fragment of synthetic polypeptide for the interaction with calnexin can restore secretion of the mutated protein in the bronchia.
- CMSP Cells presenting the antigen
- CMSP B-EBV cells, T cells, dendritic cells
- CMSP fetal bovine serum
- T cells T cells
- dendritic cells Cells presenting the antigen
- the medium was removed and 20000 CTL cells were added to each well in 100 ⁇ l of CTL culture medium containing 25 U/ml of IL2.
- 50 ⁇ l of supernatant was collected and the ⁇ interferon was measured by an ELISA (Diaclone) test.
- the cells were fixed with 1% paraformaldehyde for 10 minutes at ambient temperature and washed thoroughly before transfer into the microplates.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
B-X
Description
- This application is a divisional of U.S. application Ser. No. 12/347,677, filed Dec. 31, 2008, which is a divisional of U.S. patent application Ser. No. 10/443,614, filed May 21, 2003, which is a divisional of U.S. patent application Ser. No. 09/484,471, filed Jan. 18, 2000, now U.S. Pat. No. 6,613,882, which is a continuation of PCT/FR98/01573, filed Jul. 17, 1998, which claims priority to French Patent Application No. 9709185, filed Jul. 18, 1997. The entire contents of each being incorporated herein by reference in their entirety.
- The invention relates to means and to their use for intracellular transport of proteins or polypeptides, also to the membrane presentation of certain epitopes.
- Retrograde transport can be defined as the movement of molecules from the cell membrane to the endoplasmic reticulum (ER), passing if necessary via the Golgi apparatus. This mechanism has been demonstrated for certain classes of proteins of the endoplasmic reticulum carrying the tetrapeptide KDEL at the carboxy terminal (or HDEL in starch). A great deal of biochemical and morphological evidence indicates that those proteins leave the endoplasmic reticulum, reach the Golgi apparatus in which modifications are made to their carbohydrate chain and are then redirected to the endoplasmic reticulum. The tetrapeptide KDEL is a retention signal which traps the peptide or protein to which it is attached in the endoplasmic reticulum, such trapping taking place by interaction at a receptor protein for the KDEL motif described by Lewis M. J. et al in Nature, 348 (6297): 162: 3, 1990, 8th November.
- Other evidence for the existence of intracellular retrograde transport arises from a study of certain bacterial toxins which enter the cytosol of eukaryotic cells after passing into the endoplasmic reticulum (Pelham et al (1992) Trends cell. Biol., 2: 183-185). A particular example which has been studied is that of the Shiga toxin from Shigella dysenteriae, also E. coli Shiga-like toxins. Such toxins are composed of two polypeptide chains; one (the A fragment) is the toxic fragment and carries a deadenylase activity which inhibits protein synthesis by acting on the 28S ribosomal RNA, while the other sub-unit (the B fragment) enables the toxin to bind to the target (O'Brien et al (1992), Curr. Top. Microbiol. Immunol. 180: 65-94). Electron microscope studies have shown that Shiga toxin can be detected in the ER of A431, Vero, and Daudi cells in particular (Sandvig et al 1992 and 1994; KHINE, 1994). Further, treating cells with a fungal metabolite which cause the loss of the Golgi apparatus structure (brefeldin A) protects the cells against Shiga toxin thus suggesting that they traverse the Golgi apparatus before reaching the ER. Finally, Kim et al (1996) have confirmed that the B fragment of the toxin is localised in the Golgi apparatus.
- The following references demonstrate the state of the art as regards retrograde transport, in particular transport of the B fragment of Shiga toxin in the ER: Sandvig et al (1992), Nature 358:510-512; Sandvig et al (1994) J Cell. Biol 126: 53-64; Kim et al (1996) J. Cell. Biol 134: 1387-1399.
- Intracellular transport is defined as the ensemble of exchanges between the different cellular compartments.
- The authors of the present application have observed that the B fragment is not only moved towards the ER, but also to the nucleus of hematopoietic lines, in particular dendritic cells and macrophages.
- The authors have shown that those cells, incubated in the presence of two micromoles of B-Gly-KDEL fragment, as described below, for 3 hours then fixed, have a reactivity with specific antibodies against the toxin in the nucleus and even in the nucleole of such cells (unpublished results) which clearly indicate the existence of intracellular transport of that fragment.
- The present invention results from observations on intracellular transport of the B fragment of Shiga toxin (B fragment) and uses its routing properties to construct a chimeric polypeptide sequence containing:
-
- either a peptide or a polypeptide of therapeutic significance bound to said fragment or any functional equivalent thereof;
- or a polynucleotide sequence carrying a sequence the expression of which is desired. The B fragment and the polynucleotide sequence are coupled using any technique which is known to the skilled person and in particular that described by Allinquant B. et al in the Journal of Cell Biology 1288 (5): 919-27 (1995).
- In addition to covalent coupling of DNA molecules or other molecules to the B fragment, coupling can be via a strong non covalent interaction. To this end and by way of example, the cDNA of the B fragment is fused with that of streptavidin or with any other avidin derivative using known methods (Johannes et al (1987), J. Biol. Chem., 272: 19554-19561).
- The protein resulting from fusion (B-streptavidin) can react with biotinylated DNA obtained by PCR using biotinylated primers, or with any other biotinylated substance. The resulting complex is bound to target cells and should be transported like the intracellular B fragment.
- A further coupling method employs site-specific biotinylation of the B fragment. To this end, the cDNA of the B fragment is fused with cDNA coding for the BirA enzyme recognition site Boer et al (1995), J. Bacterial, 177: 2572-2575; Saou et al (1996) Gene, 169: 59-64). After in vitro biotinylation, the B fragment is bound to other biotinylated molecules (such as cDNA, see above) via streptavidin or any other tetravalent avidine derivative.
- The term “functional equivalent” means any sequence derived from the B fragment by mutation, deletion or addition, and with the same routing properties as the B fragment.
- More precisely, a functional equivalent can be constituted by any fragment with the same retrograde transport properties and even intracellular transport to the nucleus as those described for the B fragment. Examples which can be cited are the B fragment of verotoxin described in the Proceedings of the National Academy of Sciences of the United States of America, 84 (13): 4364-8 1987, July, or the B fragment from ricin described by Lamb F. I. Et al in the European Journal of Biochemistry, 148(2): 265-70 (1995). After describing the particular transport properties of such fragments, the skilled person will be able to select the fragment which would be the best candidate as a vector for routing any sequence in any cellular compartment.
- Thus the present invention encompasses the use of the B fragment of Shiga toxin or any other sub unit of bacterial toxins which would have comparable activities, in particular routing properties analogous to those of fragment B, including polypeptides miming the Shiga toxin B fragment. These polypeptides, and in general these functional equivalents, can be identified by screening methods which have in common the principle of detecting the interaction between random peptide sequences and the Gb3 receptor or soluble analogues of the receptor. By way of example, phage libraries expressing random peptide sequences for selection on affinity columns comprising Gb3 or after hybridisation with soluble radioactive Gb3 analogues can be used. The glycolopid Gb3 has been identified as being the cellular receptor of the Shiga toxin (Lingwood (1993), Adv. Lipid Res., 25: 189-211). Gb3 is expressed by cells which are sensitive to the toxin and internalisation of the toxin would be permitted by an interaction with Gb3. The present inventors have demonstrated that in HeLa cells in which expression of the Gb3 receptor has been inhibited (
FIG. 1A ), the internalised B fragment is not transported into the Golgi apparatus but is accumulated in vesicular structures in the cytoplasm, principally represented by lysosomes. In the control cells, the B fragment is transported to the Golgi apparatus (FIG. 1B ). - This hypothesis, whereby in the absence of the Gb3 receptor, the B fragment is no longer transported to the biosynthesis system or secretion system, has been confirmed by biochemical experiments (
FIG. 2 ). - The inventors have demonstrated that in the presence of an inhibitor of Gb3 receptor synthesis, PPNP (+PPNP), up to 50% of the internalised B fragment is degraded in the form of TCA-soluble material, which conforms to a transport activity towards a subsequent degradation compartment such as an endosomal or lysosomal compartment. When Gb3 receptor synthesis is not inhibited (−PPNP), a much smaller proportion of internalised B fragment becomes TCA soluble. It can thus be concluded that the presence of the Gb3 receptor is necessary for addressing the B fragment to specific compartments, which tends to favour the fact the main factor in the activity of the B fragment is its binding to the Gb3 receptor.
- The present invention provides chimeric polypeptide sequences, said sequences comprising at least: the Shiga toxin B fragment or a functional equivalent thereof the carboxy-terminal end of which has bound to it one or more X polypeptides with the following formula:
-
B-X, wherein: -
- B represents the B fragment of a toxin such as the Shiga toxin, the sequence of which has been described by N. G. Seidah et al (1986), J. Biol. Chem. 261: 13928-31, and in Strockbine et al (1988), J. Bact. 170: 1116-22, or a functional equivalent thereof, or from verotoxin or from ricin (references supra);
- X represents one or more polypeptides the upper limit to the total length of which being that of compatibility with retrograde or intracellular transport.
- The present invention also provides chimeric molecules with the following structure:
-
B-X′ - where B has the same meaning as above and X′ represents a nucleotide sequence coding for a peptide sequence X the expression of which is desired, in particular an antigen epitope.
- The chimeric molecules of the invention can also comprise:
-
- a) modification sites such as an N-glycosylation site constituted by about 20 amino acids, phosphorylation sites or any sequence necessary for any maturation of the molecule;
- b) a retention signal of the tetrapeptide KDEL type (Lys-Asp-Glu-Leu) which, when it is bound to the carboxy-terminal end of resident ER proteins, causes retention after maturation of the proteins by passage into the Golgi apparatus. A discourse on the role of the retention signal in protein maturation has been provided by M. J. Lewis et al, (1992), cell, 68: 353-64.
- More generally, the chimeric polypeptide sequences can comprise:
-
- any sequence necessary for maturation of the protein in a suitable cellular system;
- any sequence necessary for recognition of a given cell type by the chimeric molecule, thus enabling selectivity of action and penetration into the cell cytoplasm.
- The common factor between all chimeric sequences with structure B-X or B-X′ is that they contain the B fragment or a functional equivalent thereof.
- The chimeric molecules of the invention enable X sequences or the expression product of X′ to be routed in the ER. When X is bound to the B fragment, retrograde transport also occurs via the Golgi apparatus and probably via the endosomes. Further, under certain conditions, the molecules of the invention can undergo maturation leading to a membrane presentation of certain epitopes contained in the chimeric polypeptide sequence.
- The term “maturation” means any process which, from a given polypeptide, leads to the emergence of peptides which themselves can be presented in a cellular compartment including the cytoplasm. Maturation can occur either by enzymatic clipping in the endoplasmic reticulum, or by transport into the cytoplasm in which the polypeptide is cleaved then the peptides obtained are again transported in the endoplasmic reticulum.
- Molecules of the class I major histocompatibiliry complex (cl I MHC) can become charged with polypeptide molecules of interest X or X′ after such cleavage and be presented on the cellular membranes.
- When the chimeric molecule of the invention consists of coupling a B fragment or its equivalent with a polynucleotide molecule or an expression vector comprising a sequence the expression of which is desired, after transcription in the nucleus then translation in the cytoplasm, the polypeptide which is synthesised can undergo the same steps of cleavage, maturation and intracellular transport as that described above for a polypeptide chimeric sequence.
- Chimeric polypeptide molecules in accordance with the invention can constitute an active principle in a therapeutic composition for immunotherapy by a mechanism which is close to biological processes regarding antigen presentation suitable for development of the immune reaction. The X fragment thus represents one or more epitopes for which membrane presentation is desired at the cell surface. The size of the X fragment is limited only by the intracellular transit capacity of the chimeric molecules under consideration.
- This approach can be envisaged both for an anti-infectious or an anti-cancer immunotherapy and for constituting an antigenic bait in certain autoimmune diseases.
- Any type of antigen presented by cl I MHC is a good candidate for selecting simple or chimeric epitopes which form part of the constructions of the invention. Examples which can be cited are:
- a) Human epitopes derived from melanoma cell proteins:
- BAGE from tyrosinase (Boel, P et al (1995), Immunite 2, 167-75);
- GAGE from gp75 (Van den Eynde, B. et al (1995), J. Exp. Med. 182, 689-98;
- tyrosinase (Brichard V. et al (1993), J. Exp. Med. 178, 489-95);
- pI5 from A/MART-1 melanoma (Coulie P. G. et al (1994), J. Exp. Med. 180, 35-42; Kawakami Y. et al (1994), J. Exp. Med. 180, 347-52);
- MAGE-1 and -3 from β-catenin (De Plaen E. et al (1994),
Immunogenetics 40, 369-9; Traversari C et al (1992), J. Exp. Med. 176, 1453-7.
b) Human epitopes derived from virus proteins involved in cancer development: - Peptides derived from E6 and E7 proteins of HPV 16 (Feltkamp M. C. et al (1993), Eur. J. ImmunoL 23, 2242-9; Davis H. L. et al (1995), Hum. Gene Ther. 6, 1447-56);
- Peptides derived from the Hbs protein of HBV (Rehermann B. et al (1995), J. Exp. Med. 181, 1047-58);
- Peptides derived from proteins from EBV (Murray R. J. et al (1992), J. Exp. Med. 176, 157-68);
- Peptide derived from cytomegalovirus.
c) Human epitopes derived from oncogenes: - p21ras (Peace D. J. (1993), J. Immunol 14, 110-4; Ciernik, I. F. et al (1995) Hybridoma 14, 139-42);
- p53 (Gnjatic S. (1995), Eur. J Immunol. 25, 1638-42).
d) Epitopes of interest in autoimmune diseases: - These epitopes can be selected from those described by Chiez, R. M. et al (1994) in Immunol.
Today 15, 155-60. - e) Epitopes of interest in infectious diseases:
- Examples of such epitopes which can be cited are those described by Furukawa K. et al (1994) in J. Clin. Invest. 94; 1830-9.
- In the constructions of the invention, X or the expression product of X′ can also represent a polypeptide sequence which can restore an intracellular transport function which has been perturbed by whatever cause. As an example, a biological molecule can be trapped in the ER due to a modification by mutation, deletion or addition of a sequence, having the effect of blocking maturation or transit of that molecule. This is the case, for example, with mutated CFTR (Δ F508) 15 where binding to a chaperone molecule such as calnexin is modified such that its release is prevented or retarded, thus preventing intracellular transit. This mutation is the cause of cystic fibrosis. Introducing a non mutated replica into the endoplasmic reticulum could displace N-glycosylated chains of the CFTR (Δ F508) glycoprotein from the interaction site with calnexin, with the result that protein transport to the plasma membrane is renewed, and the epithelial cells of the lung function normally.
- The invention also provides nucleic acid constructions, in particular DNA or cDNA comprising a sequence of nucleotides coding for the chimeric protein the structure and variations of which have been defined above. More particularly, the invention provides expression vectors or plasmids carrying the above constructions and capable of being expressed in bacterial cultures. By way of example, the expression vector can be the pSU108 plasmid described by G. F. Su et al (1992), Infect. Immun. 60: 3345-59.
- More particularly, the invention provides constructions comprising:
-
- the sequence coding for the B fragment;
- a sequence coding for one or more polypeptides the expression of which is desired. These may be epitopes the membrane expression of which is desired at the cell surface; they may also be polypeptides which can retain proteins in the Golgi apparatus; finally, they may be polypeptides which can restore a disturbed intracellular transport function.
- The construction can also comprise any nucleic acid sequence coding for a polypeptide the presence of which enables proper intracellular transport in cells intended to be treated by the molecules of the invention. In particular, it may be:
-
- a sequence coding for an N-glycosylation signal;
- a sequence coding for the KDEL retention signal.
- The polynucleotide construction of the invention is under the control of a promoter, preferably a strong promoter which can produce the correct degree of expression in bacteria into which it has been transfected.
- The invention also provides transfected bacteria comprising these constructions, and capable of producing the chimeric polypeptides or proteins of the invention.
- The host cells treated by the molecules of the invention also form part of the invention; they may be any type of cell, in particular:
-
- those which can be treated in vivo such as immune system cells which are active in triggering. cellular immunity, such as dendritic cells, macrophages or B lymphocytes;
- those which can be treated in situ such as epithelial cells for use in restoring functions which have been altered either by a genetic defect or by a metabolic perturbation;
- cancer cells.
- In general, the chimeric molecules of the invention allow a novel therapeutic method to be postulated which can overcome the problems linked to viral vectors or retroviral vectors which are normally used to integrate and express exogenous molecules in animal cells. The therapeutic method which derives from the molecules of the invention consists of directly treating the cells of a patient, either ex vivo or by direct stereotaxic application with the chimeric polypeptide sequences, or by conventional mucosal treatment methods such as aerosols.
- The invention concerns the use of chimeric polypeptide or polynucleotide sequences coding for the polypeptides of the invention in the production of therapeutic compositions in which particular polypeptides are expressed in the membranes of target cells. These polypeptides are advantageously epitopes against which the development of an immunological reaction is desired which are then presented on the surface of the immune system cells, in particular dendritic cells, macrophages or B lymphocytes. The B fragment of the Shiga toxin acts as an epitope vector enabling cells presenting antigens to be programmed.
- The present invention concerns an immunotherapeutic method consisting of increasing cellular immunity as the result of the presence of an undesirable antigen in an organism, said method consisting of causing key cells of the immune system, such as dendritic cells and macrophages, to express particular epitopes. The treatment method of the invention is aimed at triggering immunity to cellular and humoral mediation by charging the cl I or cl II MHC molecules with the epitopes of interest, after restriction in the target cells. This leads to activation of cytotoxic T cells against the antigen which it is desired to eliminate.
- The epitopes presented through the constructions of the invention originate from viral, parasitic or bacterial antigens or from any cell, organite, or micro-organism the elimination of which is desired, such as cancer cells or infected cells. The epitopes can also act as bait enabling “self” molecules recognised as foreign. antigens in autoimmune diseases to be replaced by the epitopes of the invention, thus slowing down or reducing the immune reaction.
- Examples of these epitopes have been cited above in the description of the chimeric polypeptide sequences.
- The invention also concerns the use of the chimeric molecules of the invention in the manufacture of therapeutic compositions in which the particular polypeptides which it is desired to express can restore intracellular transit of a protein the altered structure of which leads to it being trapped in the ER and to an expression deficit. This is the case for membrane expression proteins which undergo intracellular maturation, including glycosylations, sulphatations, folding etc.
- A particular example is that of mutated CFTR (A F508) wherein the attachment of a chaperone molecule such as calnexin is modified following modification of the protein; this leads to the molecule being trapped, causing cystic fibrosis, leading to a general insufficiency of exocrin secretions, in particular in the pancreas and lungs.
- The present invention concerns a therapeutic treatment method for diseases having an origin in a fault in protein secretion; the method consists of directly administering the chimeric polypeptides or administering the genetic information to the cells of patients in the form of plasmids carrying exogenic sequences coding for a peptide or polypeptide which can restore the deficient cellular function.
- This restoration can result either in supplementation of the deficient function by the polypeptide X or competition between the mutated protein and the polypeptide synthesised from the exogenic sequence for binding with a specific molecule or receptor of the cellular machinery. A particular example is the treatment of the mutant cited above, causing cystic fibrosis, by administering a vector carrying a sequence coding for the attachment site for the CFTR protein with its chaperone molecule or by direct administration of the chimeric polypeptide.
- The constructions of the invention endow the human or animal health world with a novel therapeutic means for treating diseases caused by a deficit in intracellular transit or for increasing or inducing a membrane presentation of a molecule, a polypeptide or an epitope of interest.
- Further properties of the invention will become clear from the following examples and figures.
-
FIG. 1A : HeLa cells in which expression of the Gb3 receptor has been inhibited. The internalised B fragment is not transported to the Golgi apparatus but is accumulated in the vesicular structures. -
FIG. 1B : Control HeLa cells in which the B fragment is transported to the Golgi apparatus. -
FIG. 2 : Biochemical test showing the defect in B fragment transport. -
FIG. 3 : MHC class I restricted presentation of Shiga B-Mage 1 fusion proteins at peripheral blood monocytic cells (PBMC): role of the KDEL sequence. The PBMC (5×104) were primed overnight with eitherMage 1 peptide (1 μM) orMart 1 peptide (1 μM) or Shiga B-Mage 1 fusion proteins (1 μM) with a sequence which is active (B-Mage 1-Glyc-KDEL) or inactive (B-Mage 1-Glyc-KDELGL) for recycling to the endoplasmic reticulum. After washing, 2×104 cytotoxic T cells specific for theMage 1 epitope (clone 82/30) were incubated with PBMC cells primed for 24 hours. The supernatants were then collected and tested for the production of γ interferon. -
FIG. 4 : MHC class I restricted presentation of the Shiga B-Mage 1 fusion protein by different types of cells presenting antigens. B lymphoblastoid cells (), dendritic cells (+) or clonal T cells () were primed with the soluble Shiga B-Mage 1 fusion protein, as forFIG. 3 . Presentation ofMage 1 peptides was tested using the 82/30 CTL line. -
FIG. 5 : Analysis of the specificity of the MHC class I restricted presentation of the Shiga B-Mage 1 fusion protein by lines of B lymphoblastoid cells. Cells from the BM21 (HLA-A1) or BV1 (HLA-A2) B lymphoblastoid line were primed overnight either with medium alone or withMage 1 orMart 1 synthetic peptides (1 μM, or with ShigaB-Mage 1 fusion protein (1 μM), or with Antp-Mage 1 fusion protein or with the B fragment of wild-type Shiga toxin. After washing, specific cells ofMage 1 TCL 82/30 (A) orMart 1 CTL LB373 (B) were incubated for 24 hours with primed B-EBV cells. The supernatants were then collected and tested for the production of γ interferon. - I-1) Construction of Plasmid
- The X epitope selected was the MAGE epitope, present in cancer cells of patients with melanoma. The plasmid used was the pSU1O8 plasmid described by Su et al, 1992, Infect. Immun. 60: 33-45, 3359.
- The PCR primers used were as follows:
-
SEQ ID No. 1: 5′-ACTAGCTCTGAAAAGGATGAACTTTGAGAATTCTGACTCAGAATAG CTC-3′ SEQ ID No. 2: 5′-CTTTTCAGAGCTAGTAGAATTAGGATGATAGCGGCCGCTACGAAAA ATAACTTCGC-3′ - The primers were used with specific primers from the ShigaAtpE (5′) vector
-
SEQ ID No. 3: 5′-CACTACTACGTTTTAAC-3′ SEQ ID No. 4: 5′-CGGCGCAACTATCGG-3′
to produce fragments which were cloned at the restriction sites SphI and SaII of the SU108 plasmid. - Adapter fragments containing the glycosylation site and the KDEL sequence composed of the oligonucleotides sulphate 1: ((5′-phosphorylated; 5′-GGCCGCCATCCTAATTCTACTTCT-3′ (SEQ ID No. 5) and sulphate 2 (5′-CTCAGAAGTAGAATTAGGATGGC-3′ (SEQ ID No. 6)) or sulphate 3 (5′-GAGTCTGAAAAAGATGAACTTTGATGAG-3′ (SEQ ID No. 7)) were ligatured overnight at 16° C.
- The resulting fragments were cloned at the NotI and EcoRI restriction sites of pSU108 and containing the cDNA coding for B-Glyc-KDEL.
- I-2) Purification of Proteins
- The recombinant fragments were also purified using the technique described by Su et al, 1991, cited above. In brief, E. coli cells containing recombinant expression plasmids obtained from pSU108 were cultured overnight at 30° C. The culture was then diluted 5 times in LB supplemented with 50 mg/ml of ampicillin, at 50° C. After incubation for 4 hours at 42° C., the cells were thoroughly washed with 10 mM Tris/HCL, pH 8, incubated for 10 minutes in 10 mM Tris/Hcl, pH 8; 25% sucrose, 1 mM EDTA, and finally rapidly re-suspended in a water-ice mixture containing 1 mM of PMSF and a protease inhibitor mixture (leupeptin, chymostatin, pepstatin, antipain and aprotinin). The final step led to rupture of the periplasm. After clarification, the supernatant was charged onto a QFF column (Pharmacia) and eluted with a linear gradient of NaCl in 20 mM Tris/HCl, pH 7.5. depending on the construction, the B fragment was eluted between 120 mM and 400 mM. The fractions containing the B fragment were then dialysed against 20 mM of Tris/HCl, pH 7.5, and re-charged onto a monoQ column (Pharmacia) and eluted in the same manner as before. The resulting proteins, estimated to have a degree of purity of 95% using polyacrylamide-
SDS gel 15 electrophoresis, were then stored at −80° C. until use. - I-3) Induction of a CTL Response In Vitro
- Dendritic cells (DC) were cultured using previously established protocols (Romani et al, 1994). Briefly, PBMC were taken up into suspension in Iscove medium and incubated for 2 h at 37° C. in 6-well trays. Cells which had not adhered were removed and the remaining cells were incubated at 37° C. in the presence of GM-CSF (800 U/ml) and IL-4 (500 U/ml). After 5 days culture, the IL-1∝ and IFN-γ in respective concentrations of 50 U/ml and 150 U/ml were added and incubation was continued at 30° C. for 24 h. The dendritic cells were then taken up into suspension in Iscove medium in the presence of increasing concentrations of B fragment coupled with the MAGE epitope and in the presence of 3 μg/ml of human β2-microglobulin to improve the capacity of the cells to presentation of membrane epitopes. This mixture was incubated at 30° C. for 4 hrs. DCs which had internalised the B fragment coupled to this epitope were irradiated at 5000 rad, assembled by centrifuging, taken up into suspension, and mixed with CD8+ lymphocytes (prepared from PBMC). These DC, pulsed with an antigen, and the CD8+ were then kept in co-culture in the presence of 5 ng/ml of IL-7.
- After 10 days, responsive CD8+ lymphocytes were re-stimulated by freshly prepared irradiated DCs which were then also incubated in the presence of increasing concentrations of fragment B coupled to the same epitope. The co-culture of DC and responsive CD8+ lymphocytes was continued in the presence of IL-2 and IL-7 in concentrations of 10 U/ml and 5 ng/ml respectively. This re-stimulation protocol was repeated 3 times.
- In order to measure the introduction of a CTL response, responsive CD8+ lymphocytes pre-stimulated as described above were incubated in the presence of cancer cells or cells infected with a virus. These cells, which expressed the selected epitope, were labelled with Na2 51CrO4 then brought into contact with responsive CD8+ for 5 hours (Bakker et al, 1994). The radioactivity released in the medium was then determined, enabling the cytotoxic activity of the pre-stimulated responsive CD8+ lymphocytes to be quantified.
- Results
- II-1) Morphological Study of Intracellular Transport of a B Fragment Carrying the MAGE-1 Epitope
- We have demonstrated that it is possible to fuse a peptide sequence to the carboxy-terminal end of the Shiga toxin B fragment while retaining intracellular routing of this protein towards the endoplasmic reticulum (ER). This demonstration was carried out by constructing chimeric polypeptides comprising the B fragment, the N-glycosylation site and the KDEL retention signal. As a control, the KDELGL retention signal was used, namely the inactive version of the KDEL peptide, Misendock and Rothman, 1995, J. Cell. Biol. 129: 309-319. Morphological and biochemical studies have shown that the modified B fragment is transported from the plasmid membrane via the endosomes and the Golgi apparatus to the endoplasmic reticulum. This transport is inhibited by BFA (brefeldin A fungal metabolite) and reduced by nocodazole (a microtubule depolymerisation agent).
- These experiments clearly demonstrate that intracellular routing of the fusion protein towards the endoplasmic reticulum was retained. To evaluate the potential of the B fragment as an epitope vector for anti-tumoral vaccination in vitro, the MAGE-1 epitope was added to the B-Glyc-KDEL fragment under the experimental conditions described above. The novel protein was designated B-MAGE-Glyc-KDEL. The B-MAGE-Glyc-KDEL protein was coupled with the fluorophore DTAF in order to follow its intracellular transport by confocal microscopy. After internalistion, this protein was detectable in the Golgi apparatus and in the ER of HeLa cells and Pena-EBV cells (a B lymphocyte line immortalised using the Epstein-Barr virus). These results confirm the original observations concerning the intracellular transport of the B fragment modified at its carboxy-terminal end (described above) and affirm that certain presenting cells of the hematopoietic line are capable of intemalising the B fragment and transporting the protein to the ER.
- We shall now describe these studies measuring the N-glycosylation of the B-MAGE-Glyc-KDEL protein. N-glycosylation is a modification which is carried out specifically in the ER, and we have demonstrated above that a B fragment carrying a recognition site for N-glycosylation is in fact glycosylated if it is transported to the ER.
- II-2) Study of the Presentation of the MAGE-1 Antigen by Pena-EBV Cells and Dendritic Cells Pulsed by the B-MAGE-Glvc-KDEL Protein.
- In order to evaluate the capacity of the fragment to act as an epitope vector, we used a cytotoxic T lymphocyte clone (CTL 82/30) specifically recognising the MAGE-1 epitope associated with MHC class I of cells presenting the HLA-A1 haplotype. These CTL were kept in the presence of Pena-EBV cells or dendritic cells pulsed with the B-MAGE-Glyc-KDEL protein. If the MAGE-1 epitope is presented by presenting cells, the CTL will be activated and will secrete γ interferon which (IFNγ) which is then assayed.
- The quantity of IFNγ secreted is proportional to the amplitude of the stimulation of the CTLs by the presenting cells.
- Presenting cells (Pena-EBV and dendritic, 20000 cells per round bottom microwell) were either fixed for 1 h with 4% PBS-paraformaldehyde, or were not fixed. They were than washed twice with OptiMEM before being incubated for 15 h with dilutions of the B-MAGE-Glyc-KDEL protein. The protein was tested at 4 dilutions, starting with a concentration of 10 μmM final, and diluting 5 in 5 in the OptiMEM medium (medium without serum). After 15 h, the plates were washed twice by low speed centrifuging. The CTL (CTL 82/30) were added in an amount of 5000 CTL per well in 100 μl of culture medium (ID-HS-AAG+25 U/ml of IL2). As a positive control, some CTL 82/30 were kept in the presence of line G43 (a B lymphocyte line transfected with an expression plasmid of MAGE-1). After 24 h of incubation, the supernatants were harvested to determine the quantity of IFNγ produced.
- The results are shown in Table I.
-
TABLE I Concentration of B-MAGE-Glyc- KDEL Celltype 10 μM 2 μM 0.4 μM 0.08 μM Den- Fixed 446 ± 293 821 ± 64 661 ± 18 312 ± 181 dritic Non 1557 ± 404 1315 ± 91 1231 ± 150 1174 ± 478. fixed Pena- Fixed 70 ± 47 68 ± 48 23 ± 32 4 ± 5 EBV Non 1966 ± 415 1960 ± 206 1544 ± 42 853 ± 116 fixed - The results are represented by the amount of EFNγ produced under each set of conditions (average±standard deviation; n=3).
- We can see that the dendritic cells and the Pena-EBV cells pulsed with the B-MAGE-Glyc-KDEL protein were properly recognised by the CTL, even at low concentrations of the protein. In contrast, the dendritic cells and the Pena-EBV cells which had been previously fixed were not recognised. It thus appears that endocytosis and processing of the B-MAGE-Glyc-KDEL protein had taken place. These encouraging results will now be backed up by in vitro vaccination experiments.
- Mouse dendritic cells were prepared and marked with an antigen derived from P21RAS, P53 or EP2/NER proteins to test the anti-tumoral activity, or HBV, EBV or HPV to test antiviral activity. This preparation of dendritic cells was carried out using the protocol described in 1-4) above.
- These dendritic cells were then introduced into the mouse.
- The antiviral or anti-tumoral effect was observed by subsequent treatment of these mice grafted with tumoral cells or virus expressing this antigen.
- The polypeptide sequences or polynucleotide sequences of the invention can thus advantageously constitute an active principle in a pharmaceutical composition intended for the treatment of certain cancers or certain viral or bacterial infections, from the moment when a particular epitope of said virus or said cancer cell will have been integrated into the recombinant nucleotide sequence, leading to synthesis of a chimeric polypeptide which can be restricted by the MHC class I and can be expressed on the membrane surface of immune system cells.
- The CFTR (cystic fibrosis transmembrane regulator) protein is a chlorine channel of the plasmic membrane. In the large majority of patients with cystic fibrosis, the CFTR gene carries mutations. The mutation (ΔF508) which is the most frequently observed affects intracellular routing of the CFTR protein. In fact, the mutated protein CFTR(ΔF508), which is functional as regards its ionic channel activity, remains blocked at the endoplasmic reticulum, instead of being transported to the plasmic membrane. Using the Shiga toxin B fragment, we have introduced a domain of the CFTR protein which is known to be the domain of interaction with the calnexin protein (ER “chaperone”) into the endoplasmic reticulum. This domain is fused to the carboxy-terminal end of the B fragment. We have tested whether this chimeric protein can displace N-glycosylated chains of the CFTR (ΔF508) glycoprotein from the interaction site with calnexin, with the result that the CFTR (ΔF508) protein is no longer retained in the endoplasmic reticulum and can be transported to the plasmic membrane and thus function normally.
- Firstly, we constructed a chimeric protein composed of a B fragment and the interaction domain derived from the CFTR protein. A recycle signal (the KDEL peptide) was added to the carboxy-terminal end of this protein to increase its retention in the endoplasmic reticulum. It was first verified that the novel protein was also transported in the endoplasmic reticulum of target cells. Mobilisation of CFTR(ΔF508) was studied in cells of a stable cell line, LLCPKI, transfected with the cDNA of CFTR(ΔF508). This line was established by Mlle. M. A. Costa de Beauregard and M. D. Louvard (Institut Curie, Paris, CNRS UMR 144). The CFTR (ΔF508) protein which was expressed in these cells was also endowed with an epitope tag. It was thus possible to detect the arrival of the CFTR (ΔF508) protein in the plasmic membrane by immunofluorescence. In the absence of treatment, the plasmic membrane of LLCPKI cells of the line was depleted with specific CFTR (ΔF508) tags in the plasmic membrane. While the results of these pilot experiments are promising, we are obliged to develop this approach within the context of cystic fibrosis therapy.
- The experiment described above shows that the synthetic polypeptide in which X is constituted by an interaction domain between the CFTR protein and calnexin can advantageously constitute the active principle of a therapeutic composition intended to treat cystic fibrosis. In fact, competition between the mutated interaction domain in the mutant and the fragment of synthetic polypeptide for the interaction with calnexin can restore secretion of the mutated protein in the bronchia.
- Cells presenting the antigen (CMSP, B-EBV cells, T cells, dendritic cells) were incubated in 96-well microplates in a density of 105 cells per well and pulsed at 37° C. for 4 hours or 15 hours with the antigen dissolved in 100μ1 of Iscove medium. After incubation, the medium was removed and 20000 CTL cells were added to each well in 100 μl of CTL culture medium containing 25 U/ml of IL2. After 24 hours, 50 μl of supernatant was collected and the γ interferon was measured by an ELISA (Diaclone) test. In some experiments, the cells were fixed with 1% paraformaldehyde for 10 minutes at ambient temperature and washed thoroughly before transfer into the microplates.
Claims (16)
B-X
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/952,068 US20170015719A1 (en) | 1997-07-18 | 2013-07-26 | Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9709185 | 1997-07-18 | ||
FR9709185A FR2766193B1 (en) | 1997-07-18 | 1997-07-18 | CHEMICAL POLYPEPTIDE COMPRISING FRAGMENT B OF TOXIN SHIGA AND PEPTIDES OF THERAPEUTIC INTEREST |
US09/484,471 US6613882B1 (en) | 1997-07-18 | 2000-01-18 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US10/443,614 US7488809B2 (en) | 1997-07-18 | 2003-05-21 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US12/347,677 US8524652B2 (en) | 1997-07-18 | 2008-12-31 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US13/952,068 US20170015719A1 (en) | 1997-07-18 | 2013-07-26 | Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/347,677 Division US8524652B2 (en) | 1997-07-18 | 2008-12-31 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170015719A1 true US20170015719A1 (en) | 2017-01-19 |
Family
ID=9509394
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/484,471 Expired - Lifetime US6613882B1 (en) | 1997-07-18 | 2000-01-18 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US10/443,614 Expired - Fee Related US7488809B2 (en) | 1997-07-18 | 2003-05-21 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US12/347,677 Expired - Fee Related US8524652B2 (en) | 1997-07-18 | 2008-12-31 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US13/952,068 Abandoned US20170015719A1 (en) | 1997-07-18 | 2013-07-26 | Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/484,471 Expired - Lifetime US6613882B1 (en) | 1997-07-18 | 2000-01-18 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US10/443,614 Expired - Fee Related US7488809B2 (en) | 1997-07-18 | 2003-05-21 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
US12/347,677 Expired - Fee Related US8524652B2 (en) | 1997-07-18 | 2008-12-31 | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest |
Country Status (13)
Country | Link |
---|---|
US (4) | US6613882B1 (en) |
EP (1) | EP1017715B1 (en) |
JP (2) | JP4541538B2 (en) |
CN (1) | CN1272882A (en) |
AT (1) | ATE397062T1 (en) |
AU (1) | AU750367B2 (en) |
CA (1) | CA2296711C (en) |
DE (1) | DE69839566D1 (en) |
DK (1) | DK1017715T3 (en) |
ES (1) | ES2307323T3 (en) |
FR (1) | FR2766193B1 (en) |
HK (1) | HK1030613A1 (en) |
WO (1) | WO1999003881A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999059627A2 (en) * | 1998-05-15 | 1999-11-25 | Green Allan M | Verotoxin b subunit for immunization |
EP1057895A1 (en) * | 1999-06-04 | 2000-12-06 | Lohmann Animal Health GmbH & Co. KG | Fusion protein comprising Shiga toxin 2e B subunit, (vaccine)compositions comprising it, and methods for their production |
US20040071739A1 (en) * | 1999-11-15 | 2004-04-15 | Select Therapeutics, Inc. | Methods of preparing an anti-tumor vaccine |
EP1229045A1 (en) | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
DE60203491D1 (en) * | 2002-08-02 | 2005-05-04 | Inst Curie Paris | Shiga toxin subunit B as a vector for diagnosis of tumors and drug delivery to GB3-expressing tumors |
GB0524409D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
US20100129437A1 (en) * | 2007-03-23 | 2010-05-27 | Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
EP2072060A1 (en) | 2007-12-18 | 2009-06-24 | Institut Curie | Methods and compositions for the preparation and use of toxin conjugates. |
US20090214438A1 (en) * | 2007-12-18 | 2009-08-27 | Institut Curie | Methods and compositions for the preparation and use of toxin conjugates |
CN102986214A (en) | 2010-07-06 | 2013-03-20 | 皇家飞利浦电子股份有限公司 | Generation of high dynamic range images from low dynamic range images |
EP2548571A1 (en) | 2011-07-22 | 2013-01-23 | Institut Curie | Compositions having means for targeting at least one antigen to dendritic cells |
EP2740493A1 (en) | 2012-12-05 | 2014-06-11 | Institut Curie | Conjugates of the B-subunit of Shiga toxin for anticancer therapies |
EP2740491A1 (en) | 2012-12-05 | 2014-06-11 | Institut Curie | Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy |
KR20160113158A (en) | 2014-01-27 | 2016-09-28 | 몰레큘러 템플레이츠, 인코퍼레이션. | Mhc class i epitope delivering polypeptides |
EP3058956A1 (en) | 2015-02-23 | 2016-08-24 | Institut Curie | Combined vaccination/radioterapy for cancer treatment |
CN104744594B (en) * | 2015-04-21 | 2018-09-18 | 中国人民解放军第三军医大学 | The fusion protein and its preparation method and application of hepatitis B multi-epitope and shiga toxin |
WO2016196344A1 (en) | 2015-05-30 | 2016-12-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
JP6884133B2 (en) * | 2015-07-26 | 2021-06-09 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | Cell targeting molecule containing Shiga toxin A subunit effector and CD8 + T cell epitope |
EP3608333A1 (en) | 2016-12-07 | 2020-02-12 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
US20200024312A1 (en) | 2017-01-25 | 2020-01-23 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
CN116236584B (en) * | 2023-02-20 | 2024-03-22 | 四川大学 | Polysaccharide-polypeptide conjugate for high-efficiency siRNA delivery |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2547731A1 (en) | 1983-06-27 | 1984-12-28 | Centre Nat Rech Scient | ANTITUMOR IMMUNOTOXIN, PHARMACEUTICAL PREPARATIONS CONTAINING IT AND ITS USE IN VITRO |
US5198344A (en) | 1986-07-15 | 1993-03-30 | Massachusetts Institute Of Technology | DNA sequence that encodes the multidrug resistance gene |
US5338839A (en) | 1988-04-12 | 1994-08-16 | Massachusetts Institute Of Technology | DNA encoding nestin protein |
AU657087B2 (en) * | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
JPH03205721A (en) | 1990-01-08 | 1991-09-09 | Hitachi Ltd | Gas-blast circuit-breaker |
US6197299B1 (en) | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
CA2077277A1 (en) | 1991-09-09 | 1993-03-10 | John J. Donnelly | Cellular immunity vaccines from bacterial toxin-antigen conjugates |
DE4219696A1 (en) * | 1992-02-17 | 1993-08-19 | Biotechnolog Forschung Gmbh | HYBRID DNA, PLASMIDE, OLIGOHYBRIDEPEPTIDE AND VACCINE |
AU3628193A (en) * | 1992-02-18 | 1993-09-13 | Gesellschaft Fur Biotechnologische Forschung Mbh | Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it |
US5350890A (en) | 1992-10-01 | 1994-09-27 | Gould Instrument Systems, Inc. | Contact switch device |
EP0692031B1 (en) | 1993-02-22 | 2007-04-11 | The General Hospital Corporation | Heterologous antigens in live cell vaccine strains |
US7229755B1 (en) | 1993-11-17 | 2007-06-12 | Dana Farber Cancer Institute, Inc. | Method for detection of alterations in the DNA mismatch repair pathway |
US5763165A (en) | 1994-03-10 | 1998-06-09 | Ludwig Institute For Cancer Research | Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 |
MX9703676A (en) | 1994-11-17 | 1998-03-31 | Maxim Pharm Inc | Immunogens for stimulating mucosal immunity. |
EP0739984A1 (en) | 1995-04-26 | 1996-10-30 | San Tumorforschungs-Gmbh | Bivalent polypeptides containing at least two domains |
WO1997013410A1 (en) * | 1995-10-13 | 1997-04-17 | Boston Medical Center Corporation | Hybrid molecules containing amidated polypeptide binding ligands |
JP2001500730A (en) | 1996-09-10 | 2001-01-23 | ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン | Histidine-tagged Shiga toxin and toxoid, fusion protein with the toxin and toxoid, and methods for purification and preparation thereof |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6482586B1 (en) | 1996-11-22 | 2002-11-19 | Hospital For Sick Children Research And Development Limited Partnership | Hybrid compositions for intracellular targeting |
WO1999059627A2 (en) | 1998-05-15 | 1999-11-25 | Green Allan M | Verotoxin b subunit for immunization |
-
1997
- 1997-07-18 FR FR9709185A patent/FR2766193B1/en not_active Expired - Fee Related
-
1998
- 1998-07-17 CA CA2296711A patent/CA2296711C/en not_active Expired - Fee Related
- 1998-07-17 JP JP2000503103A patent/JP4541538B2/en not_active Expired - Fee Related
- 1998-07-17 DE DE69839566T patent/DE69839566D1/en not_active Expired - Lifetime
- 1998-07-17 ES ES98939705T patent/ES2307323T3/en not_active Expired - Lifetime
- 1998-07-17 AT AT98939705T patent/ATE397062T1/en not_active IP Right Cessation
- 1998-07-17 DK DK98939705T patent/DK1017715T3/en active
- 1998-07-17 WO PCT/FR1998/001573 patent/WO1999003881A2/en active IP Right Grant
- 1998-07-17 CN CN98808796A patent/CN1272882A/en active Pending
- 1998-07-17 EP EP98939705A patent/EP1017715B1/en not_active Expired - Lifetime
- 1998-07-17 AU AU88124/98A patent/AU750367B2/en not_active Ceased
-
2000
- 2000-01-18 US US09/484,471 patent/US6613882B1/en not_active Expired - Lifetime
-
2001
- 2001-01-11 HK HK01100304A patent/HK1030613A1/en not_active IP Right Cessation
-
2003
- 2003-05-21 US US10/443,614 patent/US7488809B2/en not_active Expired - Fee Related
-
2008
- 2008-12-31 US US12/347,677 patent/US8524652B2/en not_active Expired - Fee Related
-
2010
- 2010-02-26 JP JP2010041730A patent/JP2010180216A/en active Pending
-
2013
- 2013-07-26 US US13/952,068 patent/US20170015719A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2010180216A (en) | 2010-08-19 |
CA2296711C (en) | 2012-07-03 |
ATE397062T1 (en) | 2008-06-15 |
DK1017715T3 (en) | 2008-10-06 |
JP4541538B2 (en) | 2010-09-08 |
AU8812498A (en) | 1999-02-10 |
HK1030613A1 (en) | 2001-05-11 |
WO1999003881A2 (en) | 1999-01-28 |
DE69839566D1 (en) | 2008-07-10 |
US6613882B1 (en) | 2003-09-02 |
US20040047883A1 (en) | 2004-03-11 |
US20100322913A1 (en) | 2010-12-23 |
US8524652B2 (en) | 2013-09-03 |
FR2766193A1 (en) | 1999-01-22 |
ES2307323T3 (en) | 2008-11-16 |
US7488809B2 (en) | 2009-02-10 |
EP1017715A2 (en) | 2000-07-12 |
CN1272882A (en) | 2000-11-08 |
JP2001510030A (en) | 2001-07-31 |
AU750367B2 (en) | 2002-07-18 |
EP1017715B1 (en) | 2008-05-28 |
WO1999003881A3 (en) | 2000-06-29 |
CA2296711A1 (en) | 1999-01-28 |
FR2766193B1 (en) | 2001-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8524652B2 (en) | Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest | |
JP3491896B2 (en) | Immunomodulatory peptide | |
TW517061B (en) | Modified/chimeric superantigens and their use | |
EP0671926B1 (en) | Immunomodulatory peptides | |
JP5006998B2 (en) | MHC class II antigen presentation system and CD4 + T cell activation method | |
EP1417229B1 (en) | Methods and compounds for the targeting of protein to exosomes | |
JP2865300B2 (en) | Human B cell stimulating factor 2 receptor protein | |
EP1222289B1 (en) | Chimeric immunogenic compositions and nucleic acids encoding them | |
EP0789776B1 (en) | Nucleic acid transfer system | |
CA2133999A1 (en) | Recombinant mutants for inducing specific immune responses | |
WO2002061105A2 (en) | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) | |
US20120301871A1 (en) | Comparative ligand mapping from mhc positive cells | |
US6579676B1 (en) | Rapid mutational analysis method and compositions | |
KR20020068040A (en) | Chimeric immunogenic compositions and nucleic acids encoding them | |
WO2000020445A2 (en) | Tumor antigens and ctl clones isolated by a novel procedure | |
Qazi et al. | Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene | |
EP1806142B1 (en) | Method for the production of (poly)peptides by using truncated variants of the SV 40 large T antigen with an intact N terminus | |
US20050003483A1 (en) | Comparative ligand mapping from MHC class 1 positive cells | |
EP1625151A2 (en) | Comparative ligand mapping from mhc class i positive cells | |
ten Broeke | Processing of MHC class II in dendritic cells | |
JP2003289887A (en) | Immunomodulatory peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CENTRE NATIONAL DE AL RECHERCHE SCIENTIFIQUE, FRAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOULD, BRUNO;JOHANNES, LUDGER;REEL/FRAME:031295/0069 Effective date: 20000510 Owner name: INSTITUT CURIE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOULD, BRUNO;JOHANNES, LUDGER;REEL/FRAME:031295/0069 Effective date: 20000510 Owner name: UNIVERSITE PIERRE ET MARIE CURIE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOULD, BRUNO;JOHANNES, LUDGER;REEL/FRAME:031295/0069 Effective date: 20000510 Owner name: INSERM, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOULD, BRUNO;JOHANNES, LUDGER;REEL/FRAME:031295/0069 Effective date: 20000510 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |